RDPAC Executive Committee voted to approve the application of Ping An-Shionogi Co.,Ltd. (hereinafter referred to as "Ping An-Shionogi") to join RDPAC as of July 1, 2024. With the admission of Ping An-Shionogi, RDPAC now has a membership of 46 multinational pharmaceutical companies with R&D capabilities. RDPAC remains committed to being a valued partner in delivering the "Healthy China 2030" goals to improve the quality of life of people in China.
|
Tatsumori Yoshida |
"I am really pleased that Ping An-Shionogi could join RDPAC. Our company was established in 2020 as a joint venture between Shionogi Co., Ltd. of Japan and Ping An Insurance Group of China. Even we have only experienced the pharmaceutical business for a short period in China, we would like to deliver innovative pharmaceuticals of our parent company, Shionogi, as well as advocating local participation in global R&D and clinical trials. In the future, we would like to commit to the activities of RDPAC and to contributing to ‘Healthy China’."
|
Jean-Christophe Pointeau |
"On behalf of the RDPAC Executive Committee, I would like to extend a warm welcome to Ping An-Shionogi upon becoming a RDPAC member. RDPAC and its member companies have witnessed and contributed to the development of China's pharmaceutical and healthcare sector, and through having introduced many innovative drugs, they have helped to satisfy the growing demands of Chinese patients. As the Chairman of the RDPAC Executive Committee, I will continue to work with all member companies, including Ping An-Shionogi, to support China in building a pharmaceutical innovation ecosystem to foster high-quality industry development, and to contribute to ‘Healthy China’ to improve the health and well-being of people in China."
